<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95730">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847456</url>
  </required_header>
  <id_info>
    <org_study_id>SFB 997 A01 WP7</org_study_id>
    <nct_id>NCT01847456</nct_id>
  </id_info>
  <brief_title>Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity</brief_title>
  <official_title>Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers will investigate if brain insulin action influences peripheral insulin
      sensitivity in healthy humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin sensitivity as measured by clamp</measure>
    <time_frame>45 minutes to 120 minutes post nasal spray</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will measure insulin sensitivity by hyperinsulinemic euglycemic clamp before and after nasal spray application. We will compare the post-spray insulin sensitivity between the two condition (insulin nasal spray vs placebo nasal spray). Furthermore, we will compare insulin sensitivity before and after nasal insulin application.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomous nervous system activity</measure>
    <time_frame>45 to 120 minutes post spray</time_frame>
    <safety_issue>No</safety_issue>
    <description>Activity of the autonomous nervous system will be estimated by heart rate variability in ECG. We will compare the post-spray autonomous nervous system activity between the two condition (insulin nasal spray vs placebo nasal spray). Furthermore, we will compare autonomous nervous system activity before and after nasal insulin application.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>insulin nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 Units of human insulin as nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasalspray containing placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human insulin as nasal spray</intervention_name>
    <arm_group_label>insulin nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &lt; 28 kg/m2

          -  normal HbA1c

          -  healthy volunteers

        Exclusion Criteria:

          -  Heparin induced thrombocytopenia (HIT)

          -  metal implants

          -  cardial diseases

          -  anemia

          -  patients taking any kind of drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Tuebingen, Internal medicine IV</name>
      <address>
        <city>Tuebingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>April 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>andreas fritsche</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>whole body insulin sensitivity</keyword>
  <keyword>insulin action in the brain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
